BBIO

BridgeBio Pharma, Inc. Common Stock

76.53

USD

BBIO Earnings Reports

Positive Surprise Ratio

BBIO beat 8 of 26 last estimates.

31%

Next Report

Date of Next Report

Feb 18, 2026

Estimate for Q4 25 (Revenue/ EPS)

$144.68M

-$0.75

Implied change from Q3 25 (Revenue/ EPS)

+19.87%

-21.05%

Implied change from Q4 24 (Revenue/ EPS)

+2359.73%

-46.43%

BridgeBio Pharma, Inc. Common Stock earnings per share and revenue

On Oct 29, 2025, BBIO reported earnings of -0.95 USD per share (EPS) for Q3 25, missing the estimate of -0.90 USD, resulting in a -4.81% surprise. Revenue reached 120.70 million, compared to an expected 108.51 million, with a 11.23% difference. The market reacted with a -4.88% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 17 analysts forecast an EPS of -0.75 USD, with revenue projected to reach 144.68 million USD, implying an decrease of -21.05% EPS, and increase of 19.87% in Revenue from the last quarter.

FAQ

What were BridgeBio Pharma, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, BridgeBio Pharma, Inc. Common Stock reported EPS of -$0.95, missing estimates by -4.81%, and revenue of $120.70M, 11.23% above expectations.

How did the market react to BridgeBio Pharma, Inc. Common Stock's Q3 2025 earnings?

The stock price moved down -4.88%, changed from $66.62 before the earnings release to $63.37 the day after.

When is BridgeBio Pharma, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 18, 2026.

What are the forecasts for BridgeBio Pharma, Inc. Common Stock's next earnings report?

Based on 17 analysts, BridgeBio Pharma, Inc. Common Stock is expected to report EPS of -$0.75 and revenue of $144.68M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.